DBV Technologies S.A. (NASDAQ:DBVT - Get Free Report) was the recipient of a significant decrease in short interest during the month of April. As of April 15th, there was short interest totalling 161,900 shares, a decrease of 71.2% from the March 31st total of 561,900 shares. Based on an average daily trading volume, of 395,800 shares, the short-interest ratio is currently 0.4 days. Approximately 0.6% of the company's stock are sold short.
Analyst Ratings Changes
A number of research analysts have recently issued reports on DBVT shares. JMP Securities lifted their price objective on shares of DBV Technologies from $10.00 to $15.00 and gave the company a "market outperform" rating in a report on Thursday. StockNews.com assumed coverage on DBV Technologies in a research note on Thursday. They issued a "hold" rating for the company.
Check Out Our Latest Stock Analysis on DBV Technologies
DBV Technologies Stock Performance
DBVT traded up $0.34 during mid-day trading on Friday, reaching $8.95. 102,839 shares of the stock were exchanged, compared to its average volume of 183,749. DBV Technologies has a 1 year low of $2.20 and a 1 year high of $9.89. The stock has a market capitalization of $245.14 million, a PE ratio of -1.99 and a beta of -0.08. The company has a 50 day moving average price of $6.28 and a two-hundred day moving average price of $4.62.
DBV Technologies (NASDAQ:DBVT - Get Free Report) last released its quarterly earnings results on Friday, April 11th. The company reported ($1.10) earnings per share for the quarter. DBV Technologies had a negative return on equity of 106.07% and a negative net margin of 815.73%. The firm had revenue of $0.51 million for the quarter. Sell-side analysts expect that DBV Technologies will post -7.05 EPS for the current fiscal year.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in DBV Technologies stock. Boxer Capital Management LLC purchased a new stake in shares of DBV Technologies S.A. (NASDAQ:DBVT - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 50,000 shares of the company's stock, valued at approximately $154,000. Boxer Capital Management LLC owned 0.24% of DBV Technologies as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 71.74% of the company's stock.
About DBV Technologies
(
Get Free Report)
DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.
Further Reading
Before you consider DBV Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DBV Technologies wasn't on the list.
While DBV Technologies currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
